Digoxin: Cardiac Glycoside and Na+/K+ ATPase Pump Inhibitor for Heart Failure & Antiviral Research

Executive Summary: Digoxin is a potent Na⁺/K⁺ ATPase pump inhibitor and classic cardiac glycoside, primarily applied in heart failure and arrhythmia research (APExBIO product page). It enhances cardiac contractility via increased intracellular calcium. In preclinical models, digoxin demonstrates antiviral efficacy against chikungunya virus (CHIKV) in human osteosarcoma (U-2 OS) cells, primary human synovial fibroblasts, and Vero cells, but not in murine or mosquito cells. Digoxin is supplied as a solid, HPLC/NMR-verified at >98% purity, with a molecular weight of 780.94 and chemical formula C₄₁H₆₄O₁₄. Experimental protocols require DMSO for dissolution and light-protected, 4°C storage. (APExBIO, Sun et al. 2025).

Biological Rationale

Digoxin is a member of the cardiac glycoside family, historically used to manage cardiac dysfunction and arrhythmias. Its primary action is the inhibition of the Na⁺/K⁺ ATPase pump in cardiac myocytes, leading to increased intracellular calcium and augmented myocardial contractility. Congestive heart failure (CHF) and arrhythmias remain leading causes of morbidity and mortality worldwide, necessitating robust, mechanism-based agents for both translational and basic research (Digoxin: Advanced Mechanistic Insights for Heart Failure). Digoxin also exhibits antiviral activity, notably against chikungunya virus, expanding its relevance to virology research. These dual roles make digoxin a reference compound for cardiovascular and antiviral investigations (Digoxin in Translational Research: Beyond Cardiac Glycosides).

Mechanism of Action of Digoxin

Digoxin acts as a competitive inhibitor of the Na⁺/K⁺ ATPase pump. This inhibition increases intracellular Na⁺ levels, which in turn reduces the activity of the sodium-calcium exchanger (NCX), leading to accumulation of intracellular Ca²⁺. The elevated Ca²⁺ enhances actin-myosin cross-bridge formation, resulting in increased myocardial contractility (positive inotropy). Digoxin's effect on the Na⁺/K⁺ ATPase is dose-dependent and cell type-specific. At the molecular level:

• Inhibition occurs at nanomolar to micromolar concentrations (0.01–10 μM in antiviral assays).
• Cardiac myocytes exhibit heightened sensitivity due to isoform expression of Na⁺/K⁺ ATPase.
• In non-cardiac cells, such as U-2 OS and Vero cells, digoxin impairs viral replication via ionic disruption mechanisms (Sun et al., 2025).

For detailed mechanistic comparisons and pharmacokinetic integration, see Digoxin at the Crossroads: Mechanistic Insights and Strategies, which this article extends by offering updated experimental benchmarks and cell specificity data.

Evidence & Benchmarks

• Digoxin inhibits Na⁺/K⁺ ATPase in cardiac myocytes, resulting in increased intracellular Na⁺ and Ca²⁺, thereby enhancing contractility (Sun et al., 2025, DOI).
• Antiviral activity against CHIKV is observed in human U-2 OS cells, primary human synovial fibroblasts, and Vero cells at concentrations of 0.01–10 μM. No effect is seen in murine or mosquito cells (DOI).
• In canine models of CHF, intravenous digoxin (1–1.2 mg) reduces right atrial pressure and increases cardiac output within 30 minutes post-administration (APExBIO).
• Digoxin supplied by APExBIO (SKU B7684) is >98% pure (HPLC/NMR), with a molecular weight of 780.94, chemical formula C₄₁H₆₄O₁₄, and is soluble in DMSO at ≥33.25 mg/mL, but insoluble in water or ethanol (APExBIO).
• Short-term storage of digoxin solutions is recommended; solid form should be protected from light at 4°C for maximal stability (Best Practices for Reliable Cardiac Studies).

Applications, Limits & Misconceptions

Digoxin's validated uses include:

• Experimental modulation of cardiac contractility in in vitro and animal models.
• Arrhythmia research, particularly in atrial fibrillation and supraventricular tachycardias.
• Antiviral assays for chikungunya virus in select human and primate cell lines.
• Pharmacological interrogation of Na⁺/K⁺ ATPase signaling pathways.

This article updates and clarifies the scope compared to Reliable Tools for Cardiac and Antiviral Research by specifying concentration-dependent, cell line-specific antiviral effects and detailed solubility/storage parameters.

Common Pitfalls or Misconceptions

• Species specificity: Digoxin's antiviral effect does not extend to murine or mosquito cells—results must not be generalized across all cell types (DOI).
• Solubility: Digoxin is insoluble in water and ethanol; DMSO is required for preparation at research concentrations (APExBIO).
• Stability: Diluted digoxin solutions are not stable for long-term storage; always prepare fresh aliquots and store the solid protected from light at 4°C (Best Practices).
• Clinical vs. Research Use: Product is for research use only; not for diagnostic or therapeutic procedures in humans.
• Dosage Range: Dose-responsiveness is nonlinear at higher concentrations; titrate carefully in all model systems.

Workflow Integration & Parameters

For optimal experimental outcomes, practitioners should adhere to the following:

• Preparation: Dissolve solid digoxin in DMSO to achieve ≥33.25 mg/mL; avoid water or ethanol.
• Storage: Store solid at 4°C, protected from light. Use freshly prepared solutions for each experiment.
• Assay Design: Employ validated concentrations (0.01–10 μM for CHIKV inhibition; 1–1.2 mg/kg for animal models).
• Verification: Confirm purity (>98%) via HPLC or NMR; reference batch certificate from APExBIO.
• Control Selection: Include vehicle controls (DMSO) and relevant cell types for specificity assessment.

For scenario-driven laboratory protocols and troubleshooting, refer to Best Practices for Reliable Cardiac Studies, which this article supplements by highlighting precise storage, solubility, and purity benchmarks for reproducible research.

Conclusion & Outlook

Digoxin, as supplied by APExBIO, is a rigorously validated tool for the investigation of cardiac contractility, arrhythmia, and cell type-specific antiviral mechanisms. Its high purity and well-characterized pharmacology support experimental reproducibility across cardiovascular and virology research domains. Future directions include further dissection of Na⁺/K⁺ ATPase isoform-specific effects and expanded antiviral spectrum screening. For product specifications and protocol guidelines, consult the APExBIO Digoxin product page.